R-CHOP or R-CHOP-like regimens (i.e., R-EPOCH) have been widely employed as the first option for treating DLBCL-RT because, unlike other regimens, they can achieve a balance between activity and toxicity [11]. Here, DDIT3 is linked to diffuse large B-cell lymphoma.